Biofrontera Inc.

WOBURN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S.-based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy, today announced that it will report financial results for the third quarter ended September 30, 2026 before the market opens on Friday, November 13, 2026.

Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol

Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Institutional and Insider Ownership 20.4% of Astrazeneca shares are owned

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform